Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in those with LD. This is a retrospective cohort of adults with and without LD who were prescribed naltrexone for AUD from 2015 to 2019 in a safety‐net setting. Naltrexone hepatic safety was determined by liver enzyme changes during and after compared to before naltrexone prescription as well as rates of subsequent hospitalization and death by Kaplan‐Meier methods. Factors associated with hospitalization were examined by Cox regression. Of 160 patients prescribed naltrexone for AUD, 100 (63%) had LD and 47 (47%) of those with LD had cirrhosis (47% decompensated). The total cohort, LD, and cirrhosis groups had lower adjusted mean aspartate aminotransferase and alanine aminotransferase levels after versus before naltrexone prescription (p < 0.001). Two‐year survival was 97.7% (95% confidence interval [CI], 84.6–99.7), 95.4% (95% CI, 82.8–98.8), 90.8% (95% CI, 73.5–97.0), and 81.3% (95% CI, 41.2–93.8) in those without LD, LD without cirrhosis, cirrhosis, and decompensated cirrhosis groups (p = 0.46), respectively. Alcohol‐related 2‐year hospitalization rates were 8.2% (95% CI, 2.7–24), 27.7% (95% CI, 16.6–44.0), 40.5% (95% CI, 24.8–61.6), and 41.7% (95% CI, 23.3–66.6) for the groups without LD, LD without cirrhosis, cirrhosis, and decompensated cirrhosis (p = 0.007), respectively. Independent predictors of subsequent hospitalization were LD, (hazard ratio [HR], 3.70; 95% CI, 1.19–11.51; p = 0.02), cirrhosis (HR, 5.16; 95% CI, 1.69–15.75), and shorter duration (≤30 days) of naltrexone prescription (HR, 2.50; 95% CI, 1.l2–5.20; p = 0.01). Conclusion: Naltrexone is safe to use in patients with underlying LD, including those with compensated cirrhosis. Although encouraging, more safety data are needed for those with decompensated cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of alcoholic liver diseases
Rehm, J., Samokhvalov, A. V., & Shield, K. D. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.007 · Cited by 740
Streeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228
Kumar, A., Sharma, A., Bansal, P. D., Bahetra, M., Gill, H. K., & Kumar, R. (2020) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_201_19 · Cited by 21
Cited by
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Self-citationManagement of alcohol use disorder in patients with chronic liver disease
Mellinger, J. L., Fernandez, A. C., & Winder, G. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000145 · Cited by 52
“Because of concerns about hepatotoxicity, the use of naltrexone has been limited, but a recent retrospective study in liver disease patients suggests that this concern may be overstated.[77] However, a risk/benefit analysis should be undertaken tailored to each patient and considering the severity of AUD, the need for…”
BackgroundEndogenous opiates and behavior: 2022
Bodnar, R. J. (2023) · Peptides · doi:10.1016/j.peptides.2023.171095 · Cited by 13
Gopalakrishna, H., Ghabril, M., Gu, J., Li, Y. J., Fontana, R. J., Kleiner, D. E., Koh, C., Chalasani, N., & for the Drug-Induced Liver Injury Network (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001421 · Cited by 12
Metadata
- Authors
- Ayyala, D., Bottyan, T., Tien, C., Pimienta, M., Yoo, J., Stager, K., Gonzalez, J. L., Stolz, A., Dodge, J. L., Terrault, N. A., & Han, H.
- Venue
- Hepatology Communications
- Published
- 2022-10-25
- Volume
- 6
- Issue
- 12
- Pages
- 3433-3442
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W4307201649
- Cited by
- 59
- References
- 3
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.